I47.19 Insurance Policy Changes

ICD-10 I47.19 is officially defined as "Other supraventricular tachycardia." code I47.19 is referenced in 11 tracked payer policy changes from Independence Blue Cross, Blue Cross & Blue Shield of Mississippi, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code I47.19 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Independence Blue Cross · Effective Oct 1, 2026High impact
05.00.77g, Implantable Cardioverter Defibrillators
Independence Blue Cross updated ICD-10 diagnosis codes effective 10/01/2026 for Policy 05.00.77g (Implantable Cardioverter Defibrillators). Three codes were terminated (I42.0, I42.8, I49.8) and nine new codes were added with greater specificity, including new codes for Brugada syndrome (I49.81), catecholaminergic polymorphic ventricular tachycardia (I47.22), ventricular bigeminy (I49.82), and arrhythmogenic cardiomyopathy (I42.81). The policy itself was not fully reviewed; this is a routine annual ICD-10 code update.
Blue Cross & Blue Shield of Mississippi · Effective Oct 1, 2026Medium impact
Wearable Cardioverter Defibrillators
Prior authorization and Care Management approval are required for a wearable cardioverter defibrillator (WCD) used for ischemic cardiomyopathy following an acute myocardial infarction and for newly diagnosed nonischemic cardiomyopathy. Effective 2026-10-01, the Code Reference adds ICD-10 codes I42.00, I42.01, I42.09, I42.81, I42.89, I47.22, I49.81, I49.82, and I49.89 and removes ICD-9 diagnosis codes. A WCD is medically necessary as interim treatment for individuals who meet the ICD criteria but have a temporary contraindication to an ICD, such as a systemic infection, and as a bridge to left ventricular improvement or possible ICD implantation in the covered indications.
Independence Blue Cross · Effective Apr 1, 2026Medium impact
05.00.77f, Implantable Cardioverter Defibrillators
Independence Blue Cross updated Medical Policy 05.00.77f to version 05.00.77g, expanding coverage to address transvenous, subcutaneous, and extravascular implantable cardioverter defibrillators (ICDs). The policy reissued on 04/01/2026 communicates the Company's continuing position on ICD coverage. Transvenous and subcutaneous ICDs remain covered when medical necessity criteria are met; extravascular ICDs remain experimental/investigational and not covered.
Independence Blue Cross · Effective Apr 1, 2026Medium impact
05.00.77f, Implantable Cardioverter Defibrillators
Independence Blue Cross updated policy 05.00.77f to 05.00.77g, expanding coverage to include transvenous, subcutaneous, and extravascular implantable cardioverter defibrillators (ICDs). The policy clarifies medical necessity criteria for primary prevention across multiple cardiac conditions and explicitly excludes extravascular ICDs as experimental/investigational. Billing teams must ensure claims are coded correctly and that extravascular ICD claims are denied per policy.
Aetna · Identified Oct 2, 2026Medium impact
Cardiac Catheter Ablation (CPB 0165, reviewed 2026-08-25)
Aetna considers cardiac catheter ablation with electrophysiological studies medically necessary for listed atrial fibrillation, atrioventricular nodal reentrant tachycardia, atrial tachycardia and flutter, accessory pathway, and ventricular arrhythmia indications, each with its own clinical conditions such as symptoms, drug failure or intolerance, or a high-risk accessory pathway. Pulsed field ablation is considered an equally acceptable alternative to standard radiofrequency ablation for medically necessary indications. Ablation for all other indications is considered experimental, investigational, or unproven, and so are alcohol ablation of the vein of Marshall, the AtriCure Isolator Synergy EnCompass Clamp, cardio-neuro-ablation, intra-myocardial infusion-needle catheter ablation for ventricular tachycardia, non-invasive cardiac radio-ablation, and sinus node-sparing hybrid ablation.
Aetna · Identified Aug 17, 2026Medium impact
Lung Denervation Therapy and Lung Volume Reduction Surgery (CPB 0160, reviewed 2026-03-26)
Aetna Clinical Policy Bulletin 0160, last reviewed 03/26/2026, sets medical necessity criteria for lung volume reduction surgery (LVRS), bullectomy and FDA-approved endobronchial valves for severe emphysema. Aetna considers LVRS medically necessary when the member meets the listed selection criteria, including FEV1 less than or equal to 45% of predicted, a six-minute walk test greater than 140 meters, and CT scan evidence of bilateral emphysema. Thoracoscopic laser bullectomy, bronchoscopic thermal vapor ablation, biologic lung volume reduction and targeted lung denervation (the dNerva Lung Denervation System) are considered experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Cardiac Catheter Ablation (CPB 0165)
Aetna considers catheter ablation with electrophysiological studies medically necessary for atrial fibrillation, AVNRT, atrial tachycardia and atrial flutter, accessory pathways, and ventricular arrhythmias when the listed criteria are met, such as symptomatic AF when antiarrhythmic drugs have been ineffective, contraindicated, not tolerated or not preferred. Aetna considers catheter ablation for all other indications experimental, investigational or unproven. The policy also lists alcohol ablation of the vein of Marshall, the AtriCure Isolator Synergy EnCompass Clamp, cardio-neuro-ablation for carotid sinus hypersensitivity syncope, intra-myocardial infusion-needle catheter ablation for ventricular tachycardia, non-invasive cardiac radio-ablation, and sinus node-sparing hybrid ablation as experimental, investigational or unproven. Pulsed field ablation is considered an equally acceptable alternative to standard radiofrequency ablation for medically necessary indications.
Aetna · Identified Aug 15, 2026Medium impact
Cardiac Resynchronization Therapy and Other Pacing/Defibrillator Treatments for Heart Failure (CPB 0610, reviewed 2025-12-02)
Aetna considers FDA-approved biventricular pacemakers (cardiac resynchronization therapy) medically necessary for members with congestive heart failure who are in sinus rhythm when either NYHA class III or IV with LVEF less than or equal to 35%, QRS duration greater than or equal to 150 msec, and an optimal pharmacologic regimen of 3 months of maximally titrated doses as tolerated before implantation are met, or at least 40 days post myocardial infarction; or when NYHA class II to IV with LVEF less than or equal to 35%, left bundle branch block with QRS duration greater than or equal to 130 msec, and the same regimen or at least 40 days post MI are met. Aetna considers combination resynchronization-defibrillator devices medically necessary for members at high risk for sudden cardiac death when those criteria are met and at least one of the following applies: at least 1 episode of cardiac arrest from ventricular tachyarrhythmias, recurring poorly tolerated sustained ventricular tachycardia, a prior heart attack with documented non-sustained ventricular tachycardia and an inducible ventricular tachyarrhythmia, or a prior heart attack with LVEF less than or equal to 30%. Aetna considers left bundle branch pacing medically necessary when cardiac resynchronization therapy is indicated and left ventricular pacing cannot be accomplished, and considers biventricular pacing for atrial fibrillation, mild heart failure (NYHA class I), and anti-bradycardia pacing, wireless left ventricular endocardial pacing, His bundle pacing for cardiac resynchronization therapy, the galectin-3 test, and implantable diaphragmatic stimulation (VisCardia's VisONE system) experimental, investigational, or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Catheter Ablation as Treatment for Atrial Fibrillation
Transcatheter radiofrequency ablation, cryoablation or pulsed field ablation for atrial fibrillation may be considered medically necessary for symptomatic paroxysmal or symptomatic persistent atrial fibrillation that has failed to respond to adequate trials of antiarrhythmic medications, or as an alternative to atrioventricular nodal ablation and pacemaker insertion in individuals with class II or III congestive heart failure and symptomatic atrial fibrillation. It may also be considered medically necessary as an initial treatment for recurrent symptomatic paroxysmal atrial fibrillation (more than 1 episode, with 4 or fewer episodes in the previous 6 months) when a rhythm-control strategy is desired, and repeat ablation may be considered for recurrence of atrial fibrillation or development of atrial flutter following the initial procedure. Ablation for atrial fibrillation that does not meet these criteria is considered investigational.
Independence Blue Cross · Identified Jun 19, 2026Low impact
MA11.060h, Catheter Ablation of Cardiac Arrhythmias
Independence Blue Cross reissued Medical Policy MA11.060h on 06/10/2026 as part of their annual review process with no substantive coverage changes. CPT code 93656 narrative was revised effective 01/01/2025 due to annual CPT code updates. The policy continues to cover catheter ablation for supraventricular and ventricular arrhythmias under specified medical necessity criteria for Medicare Advantage members.
Independence Blue Cross · Identified Jun 19, 2026Low impact
MA11.060h, Catheter Ablation of Cardiac Arrhythmias
Independence Blue Cross reissued MA11.060h (now superseded by MA11.060i) as part of their annual review process on 06/10/2026. This is a routine policy reissuance with no substantive changes to coverage criteria for catheter ablation of cardiac arrhythmias. A CPT code update (93656) was processed effective 01/01/2025, but the policy itself maintains existing coverage requirements for supraventricular and ventricular arrhythmias.

Watch I47.19

Get one email when a payer policy names I47.19, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code I47.19?

There are 11 tracked policy changes affecting code I47.19, including updates from Independence Blue Cross, Blue Cross & Blue Shield of Mississippi, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code I47.19?

Payers that have issued tracked updates for code I47.19 include: Independence Blue Cross, Blue Cross & Blue Shield of Mississippi, Aetna.

How do I get notified when code I47.19 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code I47.19. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code I47.19?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

05.00.77g, Implantable Cardioverter Defibrillators

Wearable Cardioverter Defibrillators

05.00.77f, Implantable Cardioverter Defibrillators

05.00.77f, Implantable Cardioverter Defibrillators

Cardiac Catheter Ablation (CPB 0165, reviewed 2026-08-25)

Lung Denervation Therapy and Lung Volume Reduction Surgery (CPB 0160, reviewed 2026-03-26)

Cardiac Catheter Ablation (CPB 0165)

Cardiac Resynchronization Therapy and Other Pacing/Defibrillator Treatments for Heart Failure (CPB 0610, reviewed 2025-12-02)

Catheter Ablation as Treatment for Atrial Fibrillation

MA11.060h, Catheter Ablation of Cardiac Arrhythmias

MA11.060h, Catheter Ablation of Cardiac Arrhythmias

What insurance policy changes affect code I47.19?

Which payers have updated policy for code I47.19?

How do I get notified when code I47.19 policy changes?

Why do payers change policies for code I47.19?